





FIG. 1A

Cis strategy:



Trans strategy:




FIG. 1B

% RFP+/% GFP+ (72 HRS)




FIG. 2




FIG. 3A




FIG. 3B

5 / 29




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5




FIG. 5 (Cont. 1)




FIG. 5 (Cont. 2)




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B





FIG. 7C

13 / 29




FIG. 8A




FIG. 8B

FIG. 8C

14 / 29




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D

16 / 29




FIG. 11A




FIG. 11B

17 / 29




FIG. 12A




FIG. 12B




FIG. 13A






FIG. 13B






FIG. 15A




FIG. 15B




FIG. 16A




FIG. 16B




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B

24 / 29




FIG. 19




FIG. 20




FIG. 21

26 / 29




FIG. 22




FIG. 23

27 / 29




FIG. 24




FIG. 25

28 / 29




FIG. 26




FIG. 27

29 / 29




FIG. 28







FIG. 1A





FIG. 1B

Cis strategy:



Trans strategy:




FIG. 1C




FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5




FIG. 5
(continued)




FIG. 5
(continued)




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B







FIG. 7C

**FIG. 8A****FIG. 8B****FIG. 8C**




FIG. 9A




FIG. 9B




FIG. 9C






FIG. 10A






FIG. 11A




FIG. 11B




FIG. 12A



FIG. 12B




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B




FIG. 15A




FIG. 15B




FIG. 16A





FIG. 16B

LINE-1 plasmid GFP



LINE-1 mRNA




FIG. 17A






FIG. 17B

**FIG. 18A****FIG. 18B**




FIG. 19

DNA damage inducing agent:



Inhibitor of DNA repair pathways:



DNA ligase inhibitor
SCR7

miRNAs against host surveillance proteins:



miRNA to HUSH complex
TASOR protein




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24






FIG. 25

**FIG. 26****FIG. 27**




FIG. 28